Clinical prospective study of Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma

被引:13
|
作者
Li, Jinghua [1 ,2 ]
Xu, Kui [3 ]
Guo, Deliang [1 ,2 ]
Liao, Bo [1 ,2 ]
Zhu, Qian [1 ,2 ]
Wang, Haitao [1 ,2 ]
Jiang, Yaqun [2 ,3 ]
Wu, Dongde [4 ]
Xia, Xigang [5 ]
Jiang, Ping [1 ,2 ]
Tang, Shengli [1 ,2 ]
Yang, Zhiyong [1 ,2 ]
He, Yueming [1 ,2 ]
Zhang, Zhonglin [1 ,2 ]
He, Yong [2 ,3 ]
Yuan, Yufeng [1 ,2 ,6 ]
机构
[1] Wuhan Univ, Dept Hepatobiliary & Pancreat Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
[2] Clin Med Res Ctr Minimally Invas Procedure Hepatob, Wuhan, Hubei, Peoples R China
[3] Wuhan Univ, Dept Nucl Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
[4] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Hepatobiliary & Pancreat Surg, Wuhan, Hubei, Peoples R China
[5] Jingzhou Cent Hosp, Dept Hepatobiliary Surg, Jingzhou, Hubei, Peoples R China
[6] Wuhan Univ, TaiKang Ctr Life & Med Sci, Wuhan, Hubei, Peoples R China
关键词
Fibroblast activation protein; FAPI; PET/CT; Biliary tract carcinoma; CANCER-ASSOCIATED FIBROBLASTS; F-18-FDG; MANAGEMENT;
D O I
10.1007/s00259-023-06137-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PurposeThis study is to investigate the [Ga-68]Ga-DOTA-FAPI PET/CT diagnosis performance in biliary tract carcinoma (BTC) and analyze the association between [Ga-68]Ga-DOTA-FAPI PET/CT and clinical indexes. Methods A prospective study (NCT 05264688) was performed between January 2022 and July 2022. Fifty participants were scanned using [Ga-68]Ga-DOTA-FAPI and [F-18]FDG PET/CT and acquired pathological tissue. We employed the Wilcoxon signed-rank test to compare the uptake of [Ga-68]Ga-DOTA-FAPI and [F-18]FDG, and the McNemar test was used to compare the diagnostic efficacy between the two tracers. Spearman or Pearson correlation was used to assess the association between [(68) Ga]Ga-DOTA-FAPI PET/CT and clinical indexes. Results In total, 47 participants (mean age 59.09 +/- 10.98 [range 33-80 years]) were evaluated. The [Ga-68]Ga-DOTA-FAPI detection rate was greater than [F-18]FDG in primary tumors (97.62% vs. 85.71%), nodal metastases (90.05% vs. 87.06%), and distant metastases (100% vs. 83.67%). The uptake of [Ga-68]Ga-DOTA-FAPI was higher than [F-18]FDG in primary lesions (intrahepatic cholangiocarcinoma, 18.95 +/- 7.47 vs. 11.86 +/- 0.70, p = 0.001; extrahepatic cholangiocarcinoma, 14.57 +/- 6.16 vs. 8.80 +/- 4.74, p = 0.004), abdomen and pelvic cavity nodal metastases (6.91 +/- 6.56 vs. 3.94 +/- 2.83, p < 0.001), and distant metastases (pleural, peritoneum, omentum, and mesentery, 6.37 +/- 4.21 vs. 4.50 +/- 1.96, p = 0.01; bone, 12.15 +/- 6.43 vs. 7.51 +/- 4.54, p = 0.008). There was a significant correlation between [Ga-68]Ga-DOTA-FAPI uptake and fibroblast-activation protein (FAP) expression (Spearman r = 0.432, p = 0.009), carcinoembryonic antigen (CEA) (Pearson r = 0.364, p = 0.012), and platelet (PLT) (Pearson r = 0.35, p = 0.016). Meanwhile, a significant relationship between [Ga-68]Ga-DOTA-FAPI metabolic tumor volume and carbohydrate antigen199 (CA199) (Pearson r = 0.436, p = 0.002) was confirmed. Conclusion [Ga-68]Ga-DOTA-FAPI had a higher uptake and sensitivity than [F-18]FDG in the diagnosis of BTC primary and metastatic lesions. The correlation between [Ga-68]Ga-DOTA-FAPI PET/CT indexes and FAP expression, CEA, PLT, and CA199 were confirmed.
引用
收藏
页码:2152 / 2166
页数:15
相关论文
共 47 条
  • [41] Incremental Impact of [68Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI
    Szigeti, Florian
    Schweighofer-Zwink, Gregor
    Meissnitzer, Matthias
    Hauser-Kronberger, Cornelia
    Hitzl, Wolfgang
    Kunit, Thomas
    Forstner, Rosemarie
    Pirich, Christian
    Beheshti, Mohsen
    MOLECULAR IMAGING AND BIOLOGY, 2022, 24 (01) : 50 - 59
  • [42] 68Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression
    Li, Chongjiao
    Chen, Qiongrong
    Tian, Yueli
    Chen, Jie
    Xu, Kui
    Xiao, Zhiwei
    Zhong, Juan
    Wu, Jianyuan
    Wen, Bing
    He, Yong
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (04) : 527 - 532
  • [43] Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study
    Guochang Wang
    Linlin Li
    Jiarou Wang
    Jie Zang
    Jingci Chen
    Yu Xiao
    Xinrong Fan
    Lin Zhu
    Hank F. Kung
    Zhaohui Zhu
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 1499 - 1509
  • [44] Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [68Ga]Ga-PSMA-11 PET/CT Study
    Kluge, Kilian
    Einspieler, Holger
    Haberl, David
    Spielvogel, Clemens
    Stoiber, Stefan
    Vraka, Chrysoula
    Papp, Laszlo
    Wunsch, Sabine
    Egger, Gerda
    Kramer, Gero
    Grubmueller, Bernhard
    Shariat, Shahrokh
    Hacker, Marcus
    Kenner, Lukas
    Haug, Alexander
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (01) : 63 - 70
  • [45] Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT in Fumarate Hydratase-Deficient Renal Cell Carcinoma A Prospective and Single-Center Study
    Huang, Shuhui
    Liu, Haoyang
    Dai, Hongyuan
    Qi, Mengfang
    Su, Minggang
    Zeng, Hao
    Huang, Rui
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (10) : 931 - 937
  • [46] Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)
    Cerci, Juliano J.
    Fanti, Stefano
    Lobato, Enrique E.
    Kunikowska, Jolanta
    Alonso, Omar
    Medina, Sevastian
    Novruzov, Fuad
    Lengana, Thabo
    Granados, Carlos
    Kumar, Rakesh
    Rangarajan, Venkatesh
    Al-Ibraheem, Akram
    Hourani, Mukbil
    Ali, Nor S.
    Ahmad, Azra
    Keidar, Zohar
    Kucuk, Ozlem
    Elboga, Umut
    Bogoni, Mateos
    Paez, Diana
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (02) : 240 - 247
  • [47] Insights into lung cancer diagnosis and clinical management using [18F]F-fibroblast activation protein inhibitor (FAPI)-42 positron emission tomography/computed tomography (PET/CT)
    Mu, Xingyu
    Zhu, Zhuohao
    Wang, Zhenzhen
    Li, Xiaotian
    Wu, Yang
    Li, Jingze
    Zhang, Lei
    Fu, Wei
    ANNALS OF NUCLEAR MEDICINE, 2025, : 576 - 587